Frequently Asked Questions

About Our Services

There is no age limit for the generation of iPS cells, essentially allowing for their production at any age. However, be mindful that various diseases can be caused by DNA damage as we age. Generating iPS cells from damaged cells is highly undesirable, affecting the purity and quality of the cells.  It is highly advisable to create iPS cells when we are healthy.

Our iPS cell banking service is set apart by three key features. First, our iPS cells are produced from blood. The collected blood goes directly into a blood collection tube without exposure to air, thus no bacteria, viruses, or foreign substances are mixed with the sample. While iPS cells are the best cell type for medical use, the use of urine and dental cells for iPS cell manufacturing is considered difficult to guarantee sterility. Second, our cells are produced at a clinical-grade manufacturing facility that meets the international pharmaceutical quality standards for cell production. Third, we partnership with corporations all around the world, producing various somatic cells from iPS cells, enabling us to provide production support for even the most elaborative iPSC-derived cells. For more information, please click here.

iPS cells can be produced from urine and dental pulp too, however, it entails exposure to bacteria or other impurities in the air. To produce high-quality medical grade iPS cells, it is essential to collect them in a way in which they are not exposed to the external environment.

A total of approximately 30ml (2 tablespoons) of blood is collected for iPS cell production across four blood collection tubes, which includes the portion needed for virus testing.

If any infectious virus is found in the tests conducted upon blood collection, we may need to decline the iPS cell production. Also, depending on the client’s physical condition on the day of the collection, iPS cell production may become difficult. In such case, we may need to return to the blood collection procedure and start over the process.

If we are still unable to produce iPS cells from your blood for some reason, we will refund according to the cancellation policy. 

All iPS cells are frozen in multiple tubes in a safe and secure manner, to ensure plenty of backup. We also have spare liquid nitrogen tanks and a backup system to provide necessary cold storage in case of emergency.

When cryopreserved, your iPS cells will be stored until the end of your period of service contract. Once cells are cryopreserved, they will not divide again until after thawing, when they will begin to generate new cells. At this moment, there is no scientific data to assert how long iPS cells can be stored since the world’s first iPS cell ever was created in 2007 and there is no data going back beyond that point.  Experiments and studies revealed that other cells can be stored for decades, ensuring cells are readily available when patients need them.

Access to stored items is only authorized to our client. Personalized iPS cells cannot be used by others due to the mismatch in immunotype and the high risk of immune rejection.

Click here to access to the official website of  I Peace.

About iPS Cells

Template do not delete

Cancer immunotherapy, diabetes, spinal cord injury, Parkinson’s disease, age-related macular degeneration, heart disease, joint disease, and many other types of diseases are being studied.

For more information, please see What are IPS cells?

Research has progressed significantly since the successful generation of iPS cells reported in 2006. Currently, various clinical studies are being conducted using iPS cell-derived CAR-T cells for cancer immunotherapy, cardiac disease, neurological disease, diabetes, and other diseases. There are as many as 50 clinical trials in progress in the U.S., 30 in Europe, and 12 in Japan. Please do not hesitate to contact us for further information.

It is widely believed that an era is coming very soon where we can tackle human diseases by transplanting cells, as is the case of cancer immunotherapy using T cells. Moreover, there are also concrete studies on the creation of human tissues and organs using iPS cell-derived cells, not to mention the countless contributions to medicine development.

We have adopted production techniques to reduce the risk of cancer development when we generate iPS cells. We also take extra safety procedures to prove that the cancer-causing genes are not damaged in the donor cells prior to iPS cell generation.

There are three major causes of iPS cell tumorigenesis. Below is a list of the three major causes and our methods to generate iPS cells through safe and secure technologies that eliminate these causes and eradicate worries.

  1. Reactivation of the reprogramming factors (factors for producing iPS cells).
We generate iPS cells in a way that can eliminate all reprogramming factors at all events.

  2. Damage to the cell genome during iPS cell production.

In the conventional iPS cell generation method, the genome is sometimes damaged by the transporter that undesirably introduces the reprogramming factor into the cell. We have adopted a method eliminating damage to the genome to bring about any initialization factor, offering safety through our operational procedures.
  3.  Leftover iPS cells that have not fully transformed into their target cell type can cause cell malformations upon transplantation.  Organizations that produce differentiated cells such as nerve and muscle cells for transplantation take every precaution to make sure that no iPS cells remain in the cell population before transplantation.


iPS cells are expected to extend a healthy lifespan. On the other hand, they do not prevent aging or provide immortality. For example, if cancer immunotherapy using iPS cell-derived CAR-T cells is put to practical use and the treatment is successful, there is a good possibility that survival rates will increase, extending life expectancy in treated individuals.